美国食品和药物管理局批准Zurnai,一种纳米芬化水自动注射剂,用于阿片类药物过量紧急治疗. FDA approves Zurnai, a nalmefene hydrochloride auto-injector, for opioid overdose emergency treatment.
美国食品和药物管理局批准Zurnai,这是第一个纳米芬化水自注射器,用于对已知或疑似过量服用阿片类药物的成人和12岁及以上儿童的紧急治疗. The FDA has approved Zurnai, the first nalmefene hydrochloride auto-injector, for emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 and older. 单剂量预填充自动注射器仅需处方,如果迅速使用,可逆转阿片类药物过量剂量引起的呼吸抑制,镇静和低血压. The single-dose, pre-filled auto-injector is available by prescription only and can reverse respiratory depression, sedation, and low blood pressure caused by opioid overdose if administered quickly. 美国食品和药物管理局旨在增加纳尔梅芬和纳洛等选择,以减少阿片类药物过量服用及其死亡人数,而2023年阿片类药物过量服用死亡人数将超过107,000人,主要是由于非法芬太尼等合成阿片类药物. The FDA aims to increase options like nalmefene and naloxone to reduce opioid overdoses and their fatalities, with opioid overdose deaths exceeding 107,000 in 2023 primarily due to synthetic opioids like illicit fentanyl.